Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bio Equivalence Study of DOXIL and Doxorubicin in Subjects With Lymphoma, Leukemia and Carcinoma

NCT03975205 is registered in ClinicalTrials.gov with Sutphin Drugs as lead sponsor.

NCT NCT03975205
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03975205 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bio Equivalence Study of DOXIL and Doxorubicin in Subjects With Lymphoma, Leukemia and Carcinoma
Lead sponsor
Sutphin Drugs
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2019
Completion date
December 31, 2019
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma leukemia